Exploratory Study of the Efficacy and Safety of Juvista 250ng When Administered Following Excision of Ear Lobe Keloids
Status:
Completed
Trial end date:
2010-06-01
Target enrollment:
Participant gender:
Summary
This trial will explore the efficacy and safety of 250ng Juvista per Linear cm, administered
by intradermal injection following the excision of ear lobe keloids. Keloids commonly occur
after ear piercing and are usually bilateral.One ear lobe will be treated with Juvist and one
with placebo.